MoonLake Investors Face Dec. 15 Lead-Plaintiff Deadline in SDNY Securities Case
Investors have until December 15, 2025 to seek lead-plaintiff status in the SDNY case alleging misstatements about sonelokimab's touted Nanobody advantages.
Overview
- The putative class action, Peters v. MoonLake Immunotherapeutics, No. 1:25-cv-08612, is pending in the U.S. District Court for the Southern District of New York.
- Plaintiffs assert violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 tied to claims that SLK would outperform monoclonal therapies such as BIMZELX.
- The proposed class covers purchasers of MoonLake common stock from March 10, 2024 through September 29, 2025.
- MoonLake’s September 28, 2025 Phase 3 VELA update reported disappointing week-16 results with VELA-2 missing its primary endpoint, and the stock fell about 90% to $6.24 the next trading day.
- Multiple firms, including Bleichmar Fonti & Auld, Rosen, Faruqi & Faruqi, DJS Law Group, Berger Montague, Levi & Korsinsky, Bernstein Liebhard, and Robbins LLP, are soliciting investors, and no class has been certified.